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tiveness ratio (ICER) was calculated as cost ($CDN) per QALY
gained. QALYs were derived from the health assessment ques-
tionnaire (HAQ) scores collected prospectively on patients.
RESULTS: With the effectiveness-based analysis, the QALYs
gained during the 12-month monitoring period were estimated
to be 0.45 and 0.35, for the treatment and control groups respec-
tively. The resulting ICER was $167,282 (CDN) per QALY.
Using boot-strapping techniques and cost-effectiveness accept-
ability curves the 95% conﬁdence interval (CI) for the ICER was
$119,500 to $285,000 per QALY. For the efﬁcacy-based analy-
sis, the incremental QALYs gained were 0.56 and 0.35, for the
treatment and control groups respectively. This resulted in a sub-
stantially lower ICER, $81,213 per QALY [95% CI = 66,500,
103,430]. CONCLUSION: Depending on the data used for the
analysis, the resulting ICER was very different ($167,282 versus
$81,213 per QALY). This study highlights some the potential
concerns with using RCT data for estimating cost-effectiveness.
These results are consistent with, and help to explain, the dif-
ference in cost-effectiveness reported in 2 previous modeling
studies, one based on efﬁcacy data and the other based on effec-
tiveness data.
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Several cost-effectiveness studies have shown that the innovative
highly effective, but costly new biological therapies are within
acceptable ranges in rheumatoid arthritis (RA). The transfer-
ability of international results is limited. Country-speciﬁc data,
standardised methodologies are needed to study the adaptability
of cost-effectiveness models and to obtain comparable economic
evaluations. OBJECTIVES: The aim of our study was to assess
the burden and costs of the Hungarian RA population for the
purpose of further cost-effectiveness studies and modeling of bio-
logical therapies. METHODS: A cross sectional questionnaire
survey was performed in 2004 in 6 rheumatology centres focus-
ing on clinical characteristics, resource utilisation, EQ-5D and
HAQ were also used. A systematic search was performed in the
National Health Insurance Found database. RESULTS: A total
of 255 consecutive RA out-patients involved, mean age 55.3
years, females 86%, disease duration 9.12 years, HAQ 1.38,
DAS28 5.09, EQ-5D 0.46, DMARD therapy 87.9%, steroids
48%. Progression in HAQ correlates with utility (EQ-5D:
0.78–0.19). Costs: 55 % indirect costs (early retirement: 49%),
direct medical costs 28% (hospital admissions 11%); direct non-
medical costs 17% (informal care givers 15%). In 2000, 117,338
out-patient visits occurred with RA diagnosis. A total of 5089
patients were hospitalized because of RA (63528 bed-days, mean
duration 12.4 days), leading to about €1,340,000 consumption
of reimbursement. CONCLUSIONS: Our study investigated
Hungarian RA patients’ characteristics, health-care consumption
and burden of illness. The questionnaire survey included patients
with characteristics of target patients for biological therapy.
Health status utility decrease and costs increase consistently with
functional disability progression, early retirement and informal
care have major impact. Biological therapies are not reimbursed
yet in Hungary though arthritis centres network and guidelines
has been established. Our study offers standardized data for eco-
nomic analysis focusing on the adaptability of international cost-
effectiveness studies and models of biological therapies in the
Hungarian context.
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OBJECTIVES: Poor compliance/adherence has been shown to be
one of the leading causes for sub-optimal clinical beneﬁt. Overall
adherence in chronic diseases averages 50%, in rheumatoid
arthritis (RA) 50–70%. A comprehensive literature survey was
performed to explore the ﬁeld of compliance with biologic
DMARDs (bDMARDs), in particular regarding patient satisfac-
tion with different regimens, and to assess predicting factors of
compliance in RA treatment in general. METHODS: Relevant
articles were identiﬁed through search in a DIMDI Superbase (10
databases). Three search concepts were combined: compliance in
RA treatment 1) with bDMARDS, 2) with focus on different
administration modes 3) in general (reviews >1990). Addition-
ally, bibliographies and the Internet were reviewed. Juvenile
arthritis was excluded. RESULTS: Focus and approach of the
identiﬁed publications are highly varied. However, there are only
a few reliable data. So far, published compliance data with
bDMARDs are quasi limited to the ﬁrst two approved drugs.
Compliance rates of bDMARDs tend to be higher than those for
RA in general, calculated on basis of prescription reﬁlls (Olszyn-
ski 2004, Harley 2003). Patients’ preferences were evaluated in
three surveys. Two compared twice-weekly subcutaneous (SC)
injections with bi-monthly intravenous (IV) infusions, showing
a tendency in preference towards bi-monthly IV infusion. Factors
inﬂuencing compliance in RA treatment are older age, female
sex, decreased disability, and satisfactory contacts with health
care professionals (Viller 1999). Patient education showed posi-
tive (Viller 1999, Hill 2001) or no effects (Brus 1998). Less 
frequent dosing regimens (Claxton 2001) resulted in better com-
pliance, also bi-monthly IV infusion versus twice-weekly SC
injection (Jarry 2002). CONCLUSIONS: Compliance with
bDMARDs appears to be higher than with traditional RA treat-
ment. Patients’ preference regarding administration mode tends
towards IV infusion but needs further investigation, distinguish-
ing between kind and frequency of administration. Due to the
poor data compliance with bDMARDS needs further qualitative
and quantitative investigation.
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OBJECTIVES: To assess the ability of adalimumab + MTX to
improve health-related quality of life (HRQOL) in early RA and
interpret the results. METHODS: PREMIER was a 2-year study
of MTX-naïve, adult patients with early RA (<3 years) who
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received: adalimumab 40mg every other week (eow) + MTX;
adalimumab 40mg eow; or MTX monotherapy. The Short Form
36 (SF-36) was used to assess 8 domains of HRQOL at baseline,
and after 12, 26, 42, 52, 76, and 104 weeks of therapy (higher
scores indicate improvement). Scores for 4 physical and 4 mental
health concepts were aggregated into Physical Component
Summary (PCS) and Mental Component Summary (MCS)
scores. A minimum clinically important difference (MCID) is
2.5–5.0 for PCS and MCS. Criteria-based interpretation of the
PCS evaluated relationships between clinically and socially
meaningful variables. RESULTS: Baseline scores for the 799
patients were comparable between all 3 groups, and post-base-
line results were comparable for the 2 monotherapy groups.
Mean baseline PCS for the adalimumab + MTX (n = 256) and
MTX monotherapy (n = 247) groups were 31.7 and 32.2. Mean
PCS for the combination therapy group at Week 12 had
improved to 42.2 vs. 38.2 for the MTX group. The 4.5 differ-
ence in mean change from baseline was clinically meaningful and
sustained through 2 years (5.1) (p < 0.0001). Based on criteria-
based interpretation of the SF-36, differences in PCS scores
between the 2 groups indicate patients on MTX alone had an
increased likelihood of using more health resources and not
being able to work. CONCLUSIONS: Adalimumab + MTX
were superior to MTX alone in providing signiﬁcant and clini-
cally meaningful improvements in HRQOL in early RA. Signif-
icantly lower PCS at 2 years in the MTX group may mean
patients on MTX alone have greater health care utilization and
substantially greater job loss than patients on combination
therapy.
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OBJECTIVES: To investigate the ability of adalimumab therapy
to provide simultaneous, sustained long-term improvement in
two important patient-reported outcomes (health utility and
fatigue) in patients with severe RA who had failed at least one
DMARD. METHODS: The Health Utilities Index Mark 3
(HUI3) and Fatigue (FACIT-F, validated in RA) were simultane-
ously measured in a health economics companion trial to an
adalimumab pivotal study (DE011). For the ﬁrst 26 weeks
patients were followed under double-blind, randomized condi-
tions before rolling over into a long-term, open-label extension
(OLE) (n = 99). A subset of patients receiving adalimumab 40
mg every other week was evaluated for up to 170 weeks. The
HUI3 scale is 0–1, with “1” denoting perfect health and “0”
denoting death. FACIT-F scores range from 0–52, with higher
scores representing less fatigue. Changes in HUI3 of ≥0.03 and
FACIT-F of ≥4 are considered clinically meaningful. RESULTS:
Baseline patient characteristics were: female, 80%; age, 53 years;
duration of disease, 10 years; TJC (0–68), 34; SJC (0–66), 21;
HAQ score, 1.9; C-reactive protein (mg/L), 54; number of pre-
vious DMARDs: 4 (all mean values except % female). RA
patients’ baseline utility and fatigue scores were comparable (vs.
placebo) and approximately one-third of the population norm.
At week 26, mean changes from baseline in adalimumab-treated
patients were 0.18 for HUI3, and 8.54 for FACIT-F (both p <
0.001 vs. baseline). These improvements were sustained through-
out week 170. CONCLUSIONS: Adalimumab provided clini-
cally important, simultaneous improvements in health utility and
fatigue in patients with severe, active RA who had failed at least
one DMARD. These improvements were sustained over the 3-
year observation period.
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OBJECTIVE: To compare the efﬁcacy of regular treatment with
BUD/FM plus BUD/FM prn versus regular treatment with budes-
onide (BUD) and formoterol (FM) plus FM prn in the treatment
of asthmatic patients in Greece. METHODS: Moderate asth-
matic (mean FEV1 76% pred.) patients were recruited from 14
centers in Greece to participate in an open-label, randomized
prospective clinical trial. The duration of the study was seven
months with four scheduled visits: baseline, ﬁrst month, third
month and seventh month. Patients were randomized in 2
groups: Group A: BUD/FM 160/4.5 ìg bid plus BUD/FM prn and
Group B: BUD 200 ìg and FM 9 ìg bid plus FM prn. Outcome
measures included lung function, number of exacerbations and
relief inhalations, symptom control using the Asthma Control
Questionnaire (ACQ) and quality of life using the Asthma
Quality of Life Questionnaire (AQLQ). In addition, the use of
health services and side effects were recorded. RESULTS: A total
of 133 patients were recruited, 68 in Group A, and 65 in Group
B. Both groups showed a signiﬁcant improvement in ACQ at the
end of the study (p < 0.0001). Relief inhalations were signiﬁ-
cantly less in Group A (p < 0.0001) during the last study period,
between 3rd and 7th month. No statistically signiﬁcant differ-
ences were found in the other outcome measures. CONCLU-
SIONS: BUD/FM therapy plus BUD/FM as needed demonstrated
similar effectiveness in asthma control and quality of life com-
pared to treatment with BUD and FM plus FM as needed. Since
fewer relief inhalations were recorded in Group A, BUD/FM plus
BUD/FM prn treatment seems preferable for patients with
asthma.
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OBJECTIVE: To investigate whether salmeterol/ﬂuticasone pro-
pionate 50/100mcg (SFC) improves quality of life, physical func-
tioning and asthma symptoms in children with uncontrolled
asthma in primary care. METHODS: A prospective open label
study of children seven to twelve years old attending their GP
with uncontrolled asthma. SFC bd was taken for 16 weeks (w)
from enrolment. Peak expiratory ﬂow rate (PEFR) was measured
at baseline, w4 and w16, when the Paediatric Asthma Quality
of Life Questionnaire (PAQLQ) was completed. Patient diaries
